Brief: Larimar Therapeutics Q1 Net Income USD -29.281 Million
Apr 30 (Reuters) - Larimar Therapeutics Q1 basic EPS USD -0.46. Q1 operating expenses USD 31.188 million Q1 income from operations USD -31.188 million
Recent news on Larimar Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Larimar tumbles as safety concerns resurface in rare disease drug study update
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-SpaceX, Charter, Gulfport Energy
Larimar tumbles as safety concerns resurface in rare disease drug study update